Skip to content
Companies

Watershed Medical

Sustained-release bladder drug delivery for bladder cancer

Raised to date

$300K

of $10M offered across 1 Form D filing

Still open
$9.7M
Investors
3
Last filed
Apr 14, 2026

About

Watershed Medical is a clinical-stage company developing sustained-release drugs delivered directly into the bladder rather than systemically. Its lead program targets bladder cancer, including non-muscle-invasive and muscle-invasive disease, with plans to extend the platform to other urological conditions. The formulations are described as 'sustained and self-clearing', intended to hold therapeutic levels in the bladder and then clear without a retrieval procedure. The company was co-founded by trauma and acute care surgeon Topher Kinsella, MD, who serves as CEO.

A sustained-release, self-clearing intravesical formulation platform that keeps drug in contact with the bladder wall for extended periods without systemic exposure or a device-removal step, aimed at improving on both systemic therapy and conventional instillations.

Funding

  • EquityFiled Apr 14, 2026Form D
    $300K/ $10M

Product

Sustained & Self-Clearing intravesical drug delivery platform

Clinical-stage drug delivery platform

A drug formulation platform that delivers small molecules and peptides directly into the bladder, releasing therapy over a sustained period and then clearing on its own. The lead clinical program is in bladder cancer, with combination dosing planned in later stages.

  • Direct intravesical (in-bladder) delivery
  • Sustained release over an extended dwell time
  • Self-clearing, no retrieval procedure

Built for

Patients with non-muscle-invasive and muscle-invasive bladder cancer, reached through urologists and oncology centers

People on file